Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296125 · ClinicalTrials.gov registry record · Phase 3
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 674
- Enrollment target
NCT02296125: Completed Phase 3 study, sponsored by AstraZeneca.
NCT02296125 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 674 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02296125, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 674 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
Primary Outcome
Progression-free survival was defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression and was used to assess the efficacy of single agent osimertinib compared with SoC EGFR-TKI therapy as measured by PFS. The primary endpoint of PFS was based on Investigator assessment.
Interventions
- DRUG AZD9291 80 mg/40 mg + placebo
- DRUG Placebo Erlotinib 150/100mg
- DRUG Placebo Gefitinib 250 mg
- DRUG Erlotinib 150/100 mg
- DRUG Gefitinib 250 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 674 participants |
| Start Date | 2014-12-03 |
| Est. Completion | 2025-11-20 |
| Phase | Phase 3 |
What the finished NCT02296125 record still lists
NCT02296125 is an interventional study that assigns participants to a tested intervention. The registered 674 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 5 interventions - of which AZD9291 80 mg/40 mg + placebo is the first listed.
NCT02296125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02296125 about?
NCT02296125 is a clinical study titled "AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer". To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
What is the current status of trial NCT02296125?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 674 participants. The study started on 2014-12-03. Estimated completion is 2025-11-20.
What interventions are being tested in trial NCT02296125?
The interventions under investigation include: AZD9291 80 mg/40 mg + placebo (DRUG), Placebo Erlotinib 150/100mg (DRUG), Placebo Gefitinib 250 mg (DRUG), Erlotinib 150/100 mg (DRUG), Gefitinib 250 mg (DRUG).
Who is sponsoring clinical trial NCT02296125?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02296125's enrollment target sits among peer trials
674 543rd of 2000 higher than 1,457 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06335381 · 674 participants · NA
MOMs Chat and Care Study
- NCT06757634 · 674 participants · Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- NCT04788277 · 675 participants
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- NCT05356234 · 675 participants · NA
Ignite Study of the Jewish Family and Children's Service of the Suncoast, Inc.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI